Commentary By: Steven Sedlis, MD Associate Professor of Medicine, Chief, Division of Cardiology Manhattan Veterans Administration Medical Center
The 56th annual scientific session of the American College of Cardiology was held in New Orleans on March 24-27. The site of the meeting …
JAMA reported on two important “negative†trials: The results of the EVEREST trial, comparing tolvaptan (a novel vasopressin V2 receptor blocker) to placebo for the treatment of acute CHF exacerbation, indicate that this agent had no effect …